2. Academic Validation
  3. Susceptibilities of cefiderocol, meropenem-xeruborbactam, cefepime-taniborbactam, aztreonam-avibactam, and sulbactam-durlobactam against imipenem-non-susceptible Gram-negative bacilli in Taiwan

Susceptibilities of cefiderocol, meropenem-xeruborbactam, cefepime-taniborbactam, aztreonam-avibactam, and sulbactam-durlobactam against imipenem-non-susceptible Gram-negative bacilli in Taiwan

  • Int J Infect Dis. 2025 Dec 4:163:108279. doi: 10.1016/j.ijid.2025.108279.
Yan-Ru Wang 1,  Yu-Lin Lee 2,  Mei-Chen Tan 3,  Pei-Jing Chen 3,  I-Wen Huang 3,  Jui-Fen Lai 3,  Hui-Ying Wang 3,  Yih-Ru Shiau 3,  Shu-Chen Kuo 4,  Ya-Sung Yang 5
Affiliations

Affiliations

  • 1 Division of Infectious Diseases and Tropical Medicine, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical University, Taipei, Taiwan; School of Medicine, College of Medicine, National Defense Medical University, Taipei, Taiwan.
  • 2 Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan; Institute of Genomics and Bioinformatics, National Chung-Hsing University, Taichung, Taiwan; School of Medicine, Chung Shan Medical University, Taichung, Taiwan.
  • 3 National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Miaoli County, Taiwan.
  • 4 National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Miaoli County, Taiwan. Electronic address: [email protected].
  • 5 Division of Infectious Diseases and Tropical Medicine, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical University, Taipei, Taiwan; School of Medicine, College of Medicine, National Defense Medical University, Taipei, Taiwan. Electronic address: [email protected].
PMID: 41349864 DOI: 10.1016/j.ijid.2025.108279
Abstract

Objectives: To evaluate susceptibilities of novel Antibiotics against imipenem-non-susceptible (INS) Escherichia coli (INS-EC), Klebsiella pneumoniae (INS-KP), Acinetobacter baumannii (INS-AB), Pseudomonas aeruginosa (INS-PA) in Taiwan, and the potential resistance mechanisms.

Methods: The minimum inhibitory concentrations of 387 INS isolates (2020-2022) were determined by broth microdilution. Resistance genes were detected using multiplex polymerase chain reaction. Whole genome Sequencing and plasmid curing were conducted to identify potential resistance mechanisms.

Results: Cefiderocol showed >90% susceptibility across all species. The susceptibilities of meropenem-xeruborbactam (XEM), cefepime-taniborbactam (FTB), and aztreonam-avibactam (AZA) were 72-96% for 29 INS-EC; 95-97% for 138 INS-KP; and 0-95% for 135 INS-AB; and 32-70% for 85 INS-PA. Sulbactam-durlobactam (SUD) was active against 93% of INS-AB. Cefiderocol, XEM, and AZA retained >80% activity against class B carbapenemase-producing INS-EC/KP. Cefiderocol, XEM, and SUD showed >90% activity against blaOXA-23/24-like INS-AB. Reduced FTB activity in INS-EC was associated with both YRIK/YRIN insertion in penicillin-binding protein 3 (PBP3) and carbapenemase genes or blaIMP alone, whereas reduced AZA activity was linked to PBP3 alteration or blaCMY-42. CONCLUSIONS: Cefiderocol was highly effective, whereas novel β-lactam/β-lactamase inhibitors activity varied by species and carbapenemase types. PBP3 alterations reduced FTB and AZA activity in INS-EC.

Keywords

Aztreonam-avibactam; Cefepime-taniborbactam; Cefiderocol; Imipenem-non-susceptible; Meropenem-xeruborbactam; Sulbactam-durlobactam.

Figures
Products